Zobrazeno 1 - 10
of 148
pro vyhledávání: '"James E. Frampton"'
Autor:
James E. Frampton
Publikováno v:
American Journal of Cardiovascular Drugs. 23:219-230
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebb66611279278f525d34d48d5ba239a
https://doi.org/10.1007/s40256-023-00568-7
https://doi.org/10.1007/s40256-023-00568-7
Autor:
James E. Frampton
Publikováno v:
Drugs. 82:1603-1609
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::562c587e301d3c248e1ae948396e6089
https://doi.org/10.1007/s40265-022-01795-z
https://doi.org/10.1007/s40265-022-01795-z
Autor:
James E. Frampton
Publikováno v:
Drugs. 82:1591-1602
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1529b9d970ec495aefa26076acdc40af
https://doi.org/10.1007/s40265-022-01778-0
https://doi.org/10.1007/s40265-022-01778-0
Autor:
James E. Frampton
Publikováno v:
BioDrugs. 36:667-672
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20c79b1c6132e8a52888e427e466c7a0
https://doi.org/10.1007/s40259-022-00553-7
https://doi.org/10.1007/s40259-022-00553-7
Autor:
James E. Frampton
Publikováno v:
Drugs. 82:1481-1488
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2def8e1ed38895538e39c086bbadf8d7
https://doi.org/10.1007/s40265-022-01782-4
https://doi.org/10.1007/s40265-022-01782-4
Autor:
James E. Frampton
Publikováno v:
Targeted Oncology. 17:369-376
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4de8a0171f4ee9d8e2832cf7c1e1ab88
https://doi.org/10.1007/s11523-022-00883-0
https://doi.org/10.1007/s11523-022-00883-0
Autor:
James E, Frampton
Publikováno v:
Drugs. 82(16)
Darinaparsin (Darvias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e8213b3f9af8b309292c3bbdaa99679
https://pubmed.ncbi.nlm.nih.gov/36376781
https://pubmed.ncbi.nlm.nih.gov/36376781
Autor:
James E. Frampton
Publikováno v:
Drugs. 81:1787-1794
Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::314f697f858ad246ca8b190aa48c8036
https://doi.org/10.1007/s40265-021-01599-7
https://doi.org/10.1007/s40265-021-01599-7
Autor:
James E, Frampton
Publikováno v:
Drugs. 82(14)
Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ac1f46e6a528b17bfe6cbd52237627b8
https://pubmed.ncbi.nlm.nih.gov/36197638
https://pubmed.ncbi.nlm.nih.gov/36197638
Autor:
James E, Frampton
Publikováno v:
Drugs. 82(16)
Empagliflozin (JardianceCategorizing chronic heart failure (CHF) according to left ventricular ejection fraction (LVEF) is central to the management of this condition. CHF with a reduced ejection fraction (HFrEF) is characterized by a LVEF ≤ 40%; C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cfa5ae4209f48fcbbea27cf2e065e712
https://pubmed.ncbi.nlm.nih.gov/36374374
https://pubmed.ncbi.nlm.nih.gov/36374374